-
Immuno Oncology: If cancer was a pathogen, would a vaccine be able to destroy it?(Post)
Thanks to the great intuitions of brilliant scientists like Louis Pasteur, Edward Jenner, Robert Koch, Emil von Behring, Gaston Leon Ramon, Albert Sabin, Jonas Salk in the past century, the
Exosomes - Discovery, Cargo, Biogenesis & Functions(Post)by Ryan Wallis, PhD student, QMUL, Blizard Institute The microscopic world of cell biology was first explored by Robert Hooke in the 17th century and published in his work, Microgra
Car t signalling pathway · H(Page) Magrolimab: Unveiling the Role of Anti-CD47 in Cancer Research and Beyond(Post)What You Need to Know About MagrolimabWhat is Magrolimab?Magrolimab is an anti-CD47 monoclonal antibody that targets the "don't eat me" signal on cancer cells, promoting their destructio
The Next Leap in Cancer Treatment: CAR-T Cell Therapy's Journey to Mainstream Medicine(Post)For decades, the fight against cancer has been a grueling battle of attrition, with treatments often as harsh as the disease itself. But a revolutionary approach, chimeric antigen receptor (CAR)-T cel
T-cell receptor (TCR) signalling(Page) Polyclonal Vs Monoclonal antibodies: Key features (Post)Antibodies · Reagent GuideMonoclonal vs Polyclonal Antibodies: Key DifferencesMonoclonal and polyclonal antibodies are the two workhorse reagent types in research, diagnostics and therapy. Monoclonals
Filarial Infections - Tropical Diseases | Assay Genie(Post)By Juan Quintana, PhD student, University of Edinbrugh What are Neglected Tropical Diseases (NTDs)? The World Health Organ
Praluzatamab: Unveiling the Promise of CD47-Targeted Therapy in Cancer Research(Post)Quick Facts About PraluzatamabWhat is Praluzatamab?Praluzatamab is an experimental monoclonal antibody that targets CD47, a “don’t eat me” signal used by cancer cells to evade immune des
Ozuriftamab: A Closer Look at This Anti-CD47 Antibody in Cancer Immunotherapy(Post)What You Need to Know About OzuriftamabWhat is Ozuriftamab?Ozuriftamab is an investigational monoclonal antibody targeting CD47, designed to enhance immune-mediated clearance of cancer c
Antibody Structure: Overview & Insights(Post)Antibody Structure Antibody S
Decoding Parkinson's Disease: Insights into a Complex Neurological Disorder(Post)Parkinson's disease (PD) is a progressive neurological disorder that primarily affects the motor system, leading to a wide array of symptoms ranging from tremors and stiffness to bradykinesia (slo
Understanding T Cell Fatigue: Implications for Immune Function and Therapeutic Interventions(Post)T cells are central players in adaptive immunity, responsible for recognizing and eliminating infected or aberrant cells. Upon encountering antigens, T cells undergo clonal expansion and differ
Anti-Angiogenics Do Not Starve Tumours. They Open Them.(Post)Anti-angiogenic therapy does not work by starving tumours, and the trials that assumed it did are the reason the field spent a decade disappointed. Cutting off the blood supply was the original pitch
Estrogen and Breast Cancer: a Nuclear (Receptor) War(Post)By Dr. Lisa Dwane, Postdoctoral Researcher, Royal College of Surgeons in Ireland The first link between estrogen and breast cancer was made in the late 1
CD8+ T Cells: Understanding the Role of Cytotoxic T Cells in Immunity(Post)Immunology · T LymphocytesCD8+ T Cells: Cytotoxic Mechanisms, Memory and ExhaustionCD8+ T cells kill infected and transformed cells directly, and they do it with a specificity nothing else in the immu
BDNF in inflammation and neuropathologies(Post)BDNF Overview Brain-derived neurotrophic factor (BDNF) is a central mediator of neuroplasticity, a term used to describe the ability of neurons
Immunoglobulin vs Antibody: Unveiling the Intricacies(Post)In the realm of immunology, the terms "immunoglobulin" and "antibody" often find themselves used interchangeably, sparking confusion among those keen on understanding the immune system's fine deta
CD4 T-Helper Differentiation: Th1, Th2, Th17, Treg and Tfh(Post)The antigen tells a CD4 T cell to respond; the cytokine tells it what kind of response to make. A naive CD4⁺ T cell leaving the thymus is uncommitted. Within about seventy-two hours of engaging TCR/C
What are MHC Class I and II molecules?(Post)What are MHC Class I molecules? The MHC class I is a glycoprotein that is expressed on all nucleated cells of the human body. MHC class I are important in disease defense against viruses, ba